Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease

Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease

Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant...

Full description

Bibliographic Details
Main Authors: Uri Kopylov, Ernest Seidman
Format: Article
Language:English
Published: SAGE Publishing 2016-07-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756283X16638833
id doaj-4b4f81ad119848a4aa59d1168552d2c4
record_format Article
spelling doaj-4b4f81ad119848a4aa59d1168552d2c42020-11-25T03:16:34ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-283X1756-28482016-07-01910.1177/1756283X16638833Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseUri KopylovErnest SeidmanMonoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple clinical, genetic and immunopharmacological factors may impact the response to anti-TNFs. Early stratification of IBD patients by the expected risk of therapeutic failure during the induction and maintenance phases of treatment may allow for treatment optimization and potentially optimal short- and long-term outcomes. The aim of this review is to summarize the current data concerning the potential predictors of therapeutic success and failure of anti-TNFs in IBD.https://doi.org/10.1177/1756283X16638833
collection DOAJ
language English
format Article
sources DOAJ
author Uri Kopylov
Ernest Seidman
spellingShingle Uri Kopylov
Ernest Seidman
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
Therapeutic Advances in Gastroenterology
author_facet Uri Kopylov
Ernest Seidman
author_sort Uri Kopylov
title Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
title_short Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
title_full Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
title_fullStr Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
title_full_unstemmed Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
title_sort predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
publisher SAGE Publishing
series Therapeutic Advances in Gastroenterology
issn 1756-283X
1756-2848
publishDate 2016-07-01
description Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple clinical, genetic and immunopharmacological factors may impact the response to anti-TNFs. Early stratification of IBD patients by the expected risk of therapeutic failure during the induction and maintenance phases of treatment may allow for treatment optimization and potentially optimal short- and long-term outcomes. The aim of this review is to summarize the current data concerning the potential predictors of therapeutic success and failure of anti-TNFs in IBD.
url https://doi.org/10.1177/1756283X16638833
work_keys_str_mv AT urikopylov predictingdurableresponseorresistancetoantitumornecrosisfactortherapyininflammatoryboweldisease
AT ernestseidman predictingdurableresponseorresistancetoantitumornecrosisfactortherapyininflammatoryboweldisease
_version_ 1724635455290343424

Similar Items